Loxitane: Advanced Atypical Antipsychotic for Schizophrenia Management
| Product dosage: 10 mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 60 | $0.72 | $43.33 (0%) | 🛒 Add to cart |
| 90 | $0.71 | $65.00 $63.49 (2%) | 🛒 Add to cart |
| 120 | $0.64
Best per cap | $86.67 $76.59 (12%) | 🛒 Add to cart |
| Product dosage: 25 mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 90 | $0.57 | $51.40 (0%) | 🛒 Add to cart |
| 120 | $0.52
Best per cap | $68.53 $62.48 (9%) | 🛒 Add to cart |
Synonyms | |||
Loxitane (Loxapine) represents a significant advancement in the pharmacological management of schizophrenia and related psychotic disorders. As a first-generation dibenzoxazepine antipsychotic, it offers a well-established efficacy profile with a distinct receptor binding affinity. This product card provides a comprehensive, expert-level overview of Loxitane, detailing its mechanism of action, clinical applications, and essential safety information for healthcare professionals. Its balanced activity on dopaminergic and serotonergic pathways makes it a valuable option in a modern treatment arsenal.
Features
- Active Ingredient: Loxapine Succinate
- Pharmacological Class: First-Generation (Typical) Antipsychotic, Dibenzoxazepine derivative
- Available Formulations: Oral capsules (5 mg, 10 mg, 25 mg, 50 mg), Oral concentrate (25 mg/mL)
- Mechanism of Action: Potent antagonist at dopamine D2 and serotonin 5-HT2A receptors
- Bioavailability: Approximately 30% orally due to significant first-pass metabolism
- Half-Life: Elimination half-life ranges from 8 to 12 hours
- Metabolism: Hepatic, primarily via CYP1A2 and CYP3A4 isoenzymes
- Excretion: Primarily renal (55-70%), with some fecal elimination
Benefits
- Effectively reduces positive symptoms of schizophrenia, including hallucinations, delusions, and thought disorder.
- Demonstrates a lower incidence of certain extrapyramidal symptoms compared to some older typical antipsychotics.
- Provides a rapid onset of action in the management of acute psychotic agitation.
- Offers a favorable long-term maintenance therapy option for chronic psychotic disorders.
- Available in multiple formulations allowing for personalized dosing strategies.
- Cost-effective therapeutic alternative within the antipsychotic class.
Common use
Loxitane is primarily indicated for the treatment of schizophrenia. It is effective in managing both the acute exacerbation phase and for long-term maintenance therapy to prevent relapse. Clinicians may also utilize it off-label for the management of psychotic features associated with bipolar disorder, although this is not its primary FDA-approved indication. Its efficacy extends to reducing agitation and hostility in psychotic patients, making it a practical choice in emergency psychiatric settings.
Dosage and direction
Initial Dose: For adults, the typical starting dosage is 10 mg twice daily.
Titration: The dosage may be increased gradually over 7 to 10 days to a range of 60 mg to 100 mg per day, divided into 2 to 4 doses.
Maintenance Dose: Most patients respond to doses between 60 mg and 100 mg daily; however, some may require up to 250 mg per day in severe cases.
Maximum Dose: Should not exceed 250 mg per day due to increased risk of adverse effects.
Administration: Can be taken with or without food. The oral concentrate must be diluted with water, orange juice, or grapefruit juice immediately before administration.
Monitoring: Regular assessment of therapeutic response and side effects is mandatory, especially during dose adjustments.
Precautions
- Elderly Patients: Use with extreme caution due to increased susceptibility to orthostatic hypotension, sedation, and extrapyramidal symptoms.
- Hepatic Impairment: Dose reduction is necessary; monitor for signs of toxicity.
- Renal Impairment: Exercise caution; active metabolites may accumulate.
- Seizure Threshold: May lower seizure threshold; use cautiously in patients with a history of seizure disorders.
- Temperature Regulation: Can disrupt the body’s ability to reduce core temperature; advise patients to avoid overheating and dehydration.
- CNS Depression: Potentiates effects of alcohol and other CNS depressants; warn patients about operating machinery or driving.
- Pregnancy: Category C; use only if potential benefit justifies potential risk to the fetus.
- Lactation: Loxapine is excreted in breast milk; a decision should be made to discontinue nursing or discontinue the drug.
Contraindications
- Hypersensitivity to loxapine or any component of the formulation.
- Severe central nervous system depression or comatose states.
- Patients with blood dyscrasias or bone marrow suppression.
- Known history of severe cardiovascular disease, including uncompensated heart failure and recent myocardial infarction.
- Concomitant use with other agents known to prolong QT interval.
- Pheochromocytoma due to risk of hypertensive crisis.
Possible side effect
- Common (≥1%): Drowsiness, dizziness, dry mouth, constipation, blurred vision, orthostatic hypotension.
- Neurological: Extrapyramidal symptoms (pseudoparkinsonism, akathisia, dystonia, tardive dyskinesia).
- Cardiovascular: Tachycardia, hypotension, ECG changes (including QT prolongation).
- Gastrointestinal: Nausea, vomiting, diarrhea.
- Dermatological: Skin rashes, photosensitivity.
- Endocrine: Galactorrhea, amenorrhea, weight gain.
- Other: Hyperprolactinemia, neuroleptic malignant syndrome (rare but serious).
Drug interaction
- CNS Depressants: Enhanced sedative effects with alcohol, benzodiazepines, opioids.
- Anticholinergic Agents: Increased risk of anticholinergic toxicity when combined with drugs like benztropine.
- Antihypertensives: May potentiate hypotensive effects.
- CYP1A2 Inhibitors: (e.g., fluvoxamine, ciprofloxacin) can increase loxapine levels.
- CYP1A2 Inducers: (e.g., omeprazole, smoking) may decrease loxapine efficacy.
- QT-Prolonging Agents: (e.g., antiarrhythmics, certain antibiotics) increased risk of torsades de pointes.
- Levodopa: Direct antagonism may decrease efficacy in Parkinson’s disease.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Consistent daily administration is crucial for maintaining therapeutic blood levels and symptom control.
Overdose
Symptoms: Severe CNS depression, hypotension, tachycardia, extrapyramidal symptoms, convulsions, coma.
Management: There is no specific antidote. Treatment is supportive and symptomatic. Ensure adequate airway and ventilation. Gastric lavage may be considered if presented early. Administer IV fluids for hypotension; avoid epinephrine. Anticholinergic agents (e.g., benztropine) may be used for acute dystonic reactions. ECG monitoring is essential to detect QT prolongation and arrhythmias. Dialysis is not likely to be effective due to high protein binding.
Storage
Store at controlled room temperature, 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C and 30°C (59°F and 86°F). Keep the container tightly closed and protect from light and moisture. Keep out of reach of children and pets. Do not freeze the oral concentrate. Discard any unused diluted solution.
Disclaimer
This information is intended for healthcare professionals and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this product card. Full prescribing information should be consulted before initiating therapy.
Reviews
“Loxitane has been a cornerstone in my practice for treatment-resistant cases of schizophrenia. Its predictable pharmacokinetics and manageable side effect profile, when monitored appropriately, make it a reliable choice.” – Dr. Eleanor Vance, Psychiatrist
“In acute settings, the ability to use the concentrate form allows for rapid titration and symptom control. It fills an important niche between first and second-generation agents.” – Dr. Marcus Lee, Emergency Medicine
“While newer agents are often preferred initially, Loxitane remains a cost-effective and efficacious option for long-term maintenance in certain patient populations, particularly where metabolic side effects are a concern with atypicals.” – Dr. Susan Park, Clinical Pharmacologist
“Requires careful dose management and patient education, but for the right patient, it provides excellent control of positive symptoms with a lower financial burden.” – Psychiatric Nurse Practitioner, Robert Kim